Analyst: This Overlooked Drug Stock Could Double

The analyst called the stock an "emerging biopharma company"

Deputy Editor
May 13, 2019 at 11:49 AM
facebook twitter linkedin


H.C. Wainwright just initiated coverage on the drugmaker Rockwell Medical Inc (NASDAQ:RMTI). The brokerage firm started with a "buy" rating and an $11 price target, which is more than double the stock's current levels. The analyst called Rockwell, which specializes in end-stage renal disease treatments, an "emerging biopharma company."

Despite the bull note, RMTI has succumbed to broad market pressure today, down 6.8% at $4.91 at last check. Even with today's drop, the security is still holding atop the $48 region, a long-term level of resistance. Overall, the stock is up nearly 118% this year. 

RMTI Chart May 13

Rockwell Medical has been largely overlooked, with only one "strong buy" rating to its name. The consensus 12-month target price target of $11, however, is at a 124% premium to current levels, and represents an area not touched by the stock since 2015. 

Meanwhile, the 7.23 million shares sold short represents a whopping 16.2% of the stocks available float. At RMTI's average pace of trading, it would take over a month to cover all these pessimistic positions, leaving the door open for a short squeeze.  


 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners